Safety Profile

Sermorelin Side Effects & Safety

Sermorelin (GHRH 1-29) has a mild side effect profile due to its short half-life and pulsatile mechanism.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Side effects by severity

Common1 effect

Injection site reactions

Redness, swelling, itching.

Uncommon2 effects

Flushing

Usually transient and mild.

Headache

Typically mild.

Rare3 effects

Difficulty swallowing

Reported rarely; transient.

Drowsiness

Uncommon.

Hyperactivity/insomnia

If injected late in day.

Contraindications

Active malignancy
Hypersensitivity
Severe obesity (may blunt GH response)

Drug interactions

Glucocorticoids — blunt GH response
Antithyroid medications — may reduce efficacy

Special populations

Not established in pregnancy or lactation. Pediatric use was historically approved for GHD.

Safety summary

Sermorelin is well-tolerated. Its mild profile reflects its physiological mechanism — endogenous, pulsatile GH release remains under hypothalamic negative feedback.

Frequently asked

Is sermorelin safer than HGH?

Theoretically yes, because it preserves negative feedback and produces pulsatile rather than continuous GH. However, direct safety comparisons are limited.